Overview
Hindustan Bio Science Ltd is primarily engaged in manufacturing and selling pharmaceutical products, specifically in pharmaceuticals and biotechnology sectors.
The company has a diverse operational scope, transitioning from bulk drug sourcing to manufacturing finished dosage forms of pharmaceuticals.
Hindustan Bio Science holds DCGI approval for marketing the nephrology product 'Recombinant Human Erythropoietin', branded as 'EPOVIN'.
The company boasts world-class facilities for a range of pharmaceutical production, trusted globally by healthcare professionals and patients.
Originally involved in the cement industry, the firm has undergone several transformations, reflecting strategic diversification into biotech and pharmaceuticals.
- Sector
Pharmaceuticals
- Industry
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
- Market Cap
8 Cr
- Volatility
Low Risk
- P/E Ratio
57.1
- Industry P/E
28.0
- PEG Ratio
0.9
- P/B Ratio
9.1
- 52W High
10.32
- 52W Low
5.00
Financial Ratios
Sales CAGR
- 1Y
- -22.86%
- 3Y
- 23.61%
- 5Y
- -15.99%
- 10Y
- -4.75%
Profit CAGR
- 1Y
- 66.67%
- 3Y
- —
- 5Y
- 4.48%
- 10Y
- —
ROE
- TTM
- 2.56%
- 3Y
- 4.80%
- 5Y
- -29.46%
- 10Y
- -29.78%
ROCE
- TTM
- 0.67%
- 3Y
- 1.42%
- 5Y
- -10.65%
- 10Y
- -17.34%
Technicals
Oscillators
Neutral
Bearish
5
Neutral
7
Bullish
2
Overall
Bullish
Bearish
8
Neutral
8
Bullish
30
Moving Averages
Bullish
Bearish
3
Neutral
1
Bullish
28
Peers
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
21.68 | 9 Cr | 722.67 | 1.00 | 0.00 | 2.47 | 7.06 | 0.06 | |
2.00 | 8 Cr | -50.00 | 1.72 | 0.00 | -6.62 | -0.04 | -0.30 | |
7.99 | 8 Cr | 57.07 | 9.07 | 0.00 | 2.56 | 0.67 | 4.00 | |
6.12 | 6 Cr | -0.77 | 0.31 | 0.00 | -42.34 | -50.18 | -33.92 | |
21.24 | 6 Cr | -62.47 | 1.90 | 0.00 | — | — | 0.00 | |
2.28 | 5 Cr | -0.15 | 0.00 | 0.00 | 3.71 | -72.69 | -7.06 | |
13.10 | 3 Cr | 45.17 | 0.65 | 0.00 | -3.80 | 2.09 | -1.05 |
Price Chart Comparison
Documents
Actions
AI Mode
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Ask AI
